Navigation Links
New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications
Date:11/17/2009

LEIDEN, The Netherlands, November 17 /PRNewswire/ -- Top Institute Pharma (TI Pharma) has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke. Based on novel action mechanisms, new drugs may be discovered with the potential to prevent vascular complications in patients with hypertension: an opportunity to improve the quality of life for over a billion people worldwide. This collaboration, involving 3.4 million euros, 9 new research positions, unique materials and exchange of know-how, is scheduled to last 3 years.

Jan Danser, Professor of Pharmacology at Erasmus MC says: "Ideally, new antihypertensive drugs not only lower blood pressure, but also offer organ protection. Our project studies the consequences of blocking the biological pathways in cells and organs that lead to hypertension. As such, the project will pave the way towards finding new ways to better treat hypertension and its associated vascular complications." Additionally, the project will focus on finding new modalities for the treatment of fibrosis and pulmonary hypertension, especially in children.

Hypertension, or high blood pressure, is a leading risk factor for coronary heart disease, renal insufficiency, pulmonary fibrosis and stroke. Hypertension often results in vascular complications and end-organ damage: major organs like the heart, kidneys, lung, brain and eyes, which are fed by the circulatory system, are affected by fluctuations in blood pressure. The number of people suffering from high blood pressure worldwide is increasing: 1 billion people are currently affected, but estimates predict that in 2025 the number will exceed 1.5 billion. Despite the high occurrence and sometimes great burden of the disease, available treatments are far from being sufficient. For children suffering from hypertension, an adequate treatment does not even exist.

The Netherlands Heart Foundation also supports this research. Hans Stam, director of the Netherlands Heart Foundation says: "Hypertension is a major risk factor for cardiovascular diseases such as myocardial infarction, heart failure and stroke. Unfortunately, antihypertensive medication fails to lower blood pressure sufficiently in numerous cases. For instance, research funded by the Netherlands Heart Foundation showed that 25% of the patients did not benefit from treatment with ACE inhibitors. An effective treatment of hypertension is of the utmost importance in our battle against cardiovascular diseases. The Netherlands Heart Foundation welcomes this new consortium and its efforts to explore new and more effective hypertension therapies."

SOURCE Top Institute Pharma (TI Pharma)


'/>"/>
SOURCE Top Institute Pharma (TI Pharma)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. TargetEx Leads the European Cancer Research Consortium
2. Ricardo Launches Consortium to Evaluate Lubricant Challenges of Future Low Carbon Engine Technologies
3. International science consortium publishes analysis of domestic cattle genome sequence
4. PCI Biotech-led Consortium Awarded EUR1.1 m Eurostars Grant for siRNA
5. NewCardio Joins the Cardiac Safety Research Consortium
6. Genstruct Added to The Biomarker Consortiums Rapidly Growing Roster of Industry Experts
7. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
8. Noted Molecular Epidemiologist Joins Cepheid to Head Healthcare Associated Infection Consortium Program
9. Sigma-Aldrich Joins Phase 2 of The RNAi Consortium to Validate shRNA Libraries
10. The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium
11. Advanced Energy Consortium will develop micro and nanosensors to boost energy production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... N.J. and PETACH TIKVAH, Israel ... BCLI), a leading developer of adult stem cell technologies for ... Executive Officer, will present at the Alliance for Regenerative Medicine,s ... Day on Thursday, April 27, 2017 at 09:40 EDT in ... Ralph Kern , MD, MHSc, Chief Medical Officer & ...
(Date:4/19/2017)... ... April 18, 2017 , ... ... been a key device for generating monodisperse droplets of known diameters for research ... for generating monodisperse solid particles by drying monodisperse droplets. , The VOAG ...
(Date:4/19/2017)... ... ... Alisa Wright, founder and CEO of Singota Solutions , has received ... Lafayette, Indiana. , The Distinguished Alumni Award was established in 1984 to honor ... endeavors. , Wright began her career in the pharmaceutical industry with firms such ...
(Date:4/19/2017)... ... ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial in ... Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. announced today ... its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. , ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 2017 The research team of The Hong ... fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery and ... speed and accuracy for use in identification, crime investigation, immigration control, ... ... A research team led ...
Breaking Biology News(10 mins):